Antegenes

Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.

Antegenes headquartered in Europe, operates in the Biotechnology, Health Care, Genetics sector. The company focuses on Biotechnology and has secured $154.7M in funding across 48 round(s). With a team of 1-10 employees, Antegenes is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Antegenes, raised $711.0K. Discover more about their projects, partnerships, and impact on our platform.